# A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

> **NCT02337725** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 244 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** TVP-1012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02337725
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-07
- **Primary completion:** 2016-09-15
- **Final completion:** 2016-09-15
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337725, "A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02337725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*